Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk

N/ACompletedNCT00874185

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.720 enrolled

Overview

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

12 first patients that are eligible

Study Type

OBSERVATIONAL

Enrollment

720

Sex: MALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CV risk factors * Male above 18 Exclusion Criteria: * Non-informed consent

EDITS

Time frame: 6 months

SEAR

Time frame: 6 months

Medication prescribed

Time frame: 6 months

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.